PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL	Application Number	ection of information unless it displays a valid OMB control number. 10/668,044
TRANSMITTAL	Filing Date	September 22, 2003
FORM	First Named Inventor	Cynthia C. Bamdad
(to be used for all correspondence after initial filing)	Art Unit	1645
	Examiner Name	N/A
Total Number of Pages in This Submission 6	Attorney Docket Number	M1015.70072US00

Tota	l Number of Pages in This Submission	M10	15.700720500
		ENCLOSURES (Check all that app	(y)
	Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): PTO/SB/08A, PTO/SB/08B and copies of the cited references A1-A8, B1-B6, C1-C7; and Return Receipt Postcard
	Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Total Number of Pages in Submission does no	ot include references.
	SIGNA	TURE OF APPLICANT, ATTORNEY,	OR AGENT
Firm or Individ	Joseph Hyosuk Kim, Ph.E Reg. No. 41,425 JHK Law	D.	
Signat	ire Harry	Ler, Reg. No. 56,814	
Date	October 28, 2005		
		ERTIFICATE OF TRANSMISSION/MA	II INC
sufficie	y certify that this correspondence is b	peing facsimile transmitted to the USPTO or depo	osited with the United States Postal Service with P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed	or printed name Harry Sung Lee		
Signati	Ire Ha	- 222	Date October 28, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doctor No. M1015.70072US00

date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ha Oes

Harry Lee

Applicant: Cynthia C. Bamdad

Serial No.: 10/668,044
Filed: September 22, 2003
Confirmation No.: 7297

Title: CUSTOMIZED THERAPEUTICS

AND IN SITU DIAGNOSTICS

Examiner: N/A Art Unit: 1645

Attorney Docket No.: M1015.70072US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Documents:

US 5,968,479, ITO et al., October 19, 1999			
US 6,395,257 B1, ACHILEFU et al., May 28, 2002	 		
US 6,096,289, GOLDENBERG, August 1, 2000	ं .च.च्याप्रसंदर्भर∳%	oo alaa aa a	The state of the s
US 5,990,479, WEISS et al., November 23, 1999			
US 6,207,392 B1, WEISS et al., March 27, 2001		· · · · · · · · · · · · · · · · · · ·	

US 2003/0036199 A1, BAMDAD et al., February 20, 2003

U.S. Patent Application No. 09/631,818, BAMDAD, Cynthia, filed August 3, 2000 (Abandoned)

U.S. Patent Application No. 09/602,778, BAMDAD, Cynthia, filed June 23, 2000 (Abandoned)

WO 02/056022 A2, BAMDAD et al., July 18, 2002

WO 02/39999 A2, BAMDAD et al., May 23, 2002

WO 00/43783 A2, BAMDAD et al., July 27, 2000

WO 00/43791 A2, BAMDAD et al., July 27, 2000

WO 01/92277 A1, BAMDAD et al., December 6, 2001

WO 02/01230 A2, BAMDAD et al., January 3, 2002

KNIGHT, Andrew W., "A review of recent trends in analytical applications of electrogenerated chemiluminescence", TrAC Trends in Analytical Chemistry (1999), 18(1): 47-62 (Abstract only)

KNIGHT and GREENWAY, "Occurrence, mechanisms, and analytical applications of electrogenerated chemiluminescence. A review", *The Analyst* (1994), 119(5), 879-890 (Abstract only)

STULTS et al., "Use of recombinant biotinylated aequorin in microtiter and membrane-based assays: purification of recombinant apoaequorin from Escherichia coli", *Biochemistry* (1992), 31(5): 1433-1442 (Abstract only)

MENGELING et al., "A microplate assay for analysis of solution-phase glycosyltransferase reactions: determination of kinetic constants", *Anal. Biochem.* (1991), 199(2): 286-292 (Abstract only)

HASHIMOTO et al., "Construction of the Single-Chain Fv from 196-14 Antibody toward Ovarian Cancer-Associated Antigen CA125", *Biol. Pharm. Bull.* (1999), 22(10): 1068-1072 (Abstract only)

VAUGHAN et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", *Nature Biotechnology* (1996), 14: 309-314 (Abstract only)

Zhou et al., "Expression and purification of single-chain anti-HBx antibody in Escherichia coli", J. Cancer Res. Clin. Oncol. (1997), 123: 609-613

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

Also submitted herewith are copies of the International Search Report and the International Preliminary Examination Report for International application PCT/US02/08809.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Therefore, no fee is required.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

October 28, 2005

Date

Respectfully submitted,

Hamble, Res. No. 56,814

Joseph Hyosuk Kim, Ph.D. Reg. No. 41,425 Attorney for Applicants

JHK Law

P.O. Box 1078

La Canada, CA 91012-1078

Telephone: (818) 249-8177 Facsimile: (818) 249-8277

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 1

Application Number 10/668,044

Filing Date September 22, 2003

First Named Inventor Cynthia C. Bamdad

Art Unit 1645

Examiner Name N/A

Attorney Docket Number M1015.70072US00

			U. S. PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Document Number Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A1	^{US-} 5,968,479	10-19-1999	ITO et al.	whole document	
	A2	^{US-} 6,395,257 B1	05-28-2002	ACHILEFU et al.	whole document	
	A3	^{US-} 6,096,289	08-01-2000	GOLDENBERG	whole document	
-	A4	^{US-} 5,990,479	11-23-1999	WEISS et al.	whole document	
	A5	^{US-} 6,207,392 B1	03-27-2001	WEISS et al.	whole document	
	A6	^{US-} 2003/0036199 A1	02-20-2003	BAMDAD et al.	whole document	
·	A7	us- 09/631,818 (8-3-2000)		BAMDAD, Cynthia	whole document	
	A8	US- 09/602,778 (6-23-2000)		BAMDAD, Cynthia	whole document	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	_	US-	-			
· · · · · · · · · · · · · · · · · · ·		US-				
		US-				
 -	_	US-				

	FOREIGN PATENT DOCUMENTS							
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
	110.	Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	Te		
	B1	WO 02/056022 A2	07-18-2002	BAMDAD et al.	whole document			
	B2	WO 02/39999 A2	05-23-2002	BAMDAD et al.	whole document			
	B 3	WO 00/43783 A2	07-27-2000	BAMDAD et al.	whole document			
	B4	WO 00/43791 A2	07-27-2000	BAMDAD et al.	whole document			
<u>-</u> -	B5	WO 01/92277 A1	12-06-2001	BAMDAD et al.	whole document			
	B6	WO 02/01230 A2	01-03-2002	BAMDAD et al.	whole document			

Examiner	Date	
	Date	i i
Signature	Considered	
1	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		e required to respond to a collection	Complete if Known	control number.		
		Application Number	10/668,044	····		
		Filing Date	September 22, 2003			
		First Named Inventor	Cynthia C. Bamdad			
		Art Unit	1645	·		
	(OSE as many site	eets as n	recessary)	Examiner Name	N/A	·
Sheet	1	of	1	Attorney Docket Number	M1015.70072US00	

Examiner	Cito	NON PATENT LITERATURE DOCUMENTS	_
Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	KNIGHT, Andrew W., "A review of recent trends in analytical applications of electrogenerated chemiluminescence", TrAC Trends in Analytical Chemistry (1999), 18(1): 47-62	
	C2	KNIGHT and GREENWAY, "Occurrence, mechanisms, and analytical applications of electrogenerated chemiluminescence. A review", The Analyst (1994), 119(5), 879-890	
	C3	STULTS et al., "Use of recombinant biotinylated aequorin in microtiter and membrane-based assays: purification of recombinant apoaequorin from Escherichia coli", Biochemistry (1992), 31(5): 1433-1442	
	C4	MENGELING et al., "A microplate assay for analysis of solution-phase glycosyltransferase reactions: determination of kinetic constants", Anal. Biochem. (1991), 199(2): 286-292	
	C5	HASHIMOTO et al., "Construction of the Single-Chain Fv from 196-14 Antibody toward Ovarian Cancer-Associated Antigen CA125", Biol. Pharm. Bull. (1999), 22(10): 1068-1072	
	C6	VAUGHAN et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", Nature Biotechnology (1996), 14: 309-314	
	C7	Zhou et al., "Expression and purification of single-chain anti-HBx antibody in Escherichia coli", J. Cancer Res. Clin. Oncol. (1997), 123: 609-613	

Examiner	Date
Signature	
gridial C	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.